Drawing for GLENMARK GENERICS

USPTO serial 77401483

GLENMARK GENERICS

Reviewed by CopyMark Law Group

Reg. 3998466Status 710
Filing date
Status date
Registration date
Jul 19, 2011
Examiner
WATSON, JULIE A
Law office
TMEG LAW OFFICE 109

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with GLENMARK GENERICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Hany W. Rizkalla

Hany W. Rizkalla GLENMARK PHARMACEUTICALS INC., USA750 Corporate Dr.Legal DepartmentMAHWAH, NJ 07430

Goods and services

ClassDescriptionStatusFirst use
005Opium alkaloid preparations; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Preparation for the relief of pain; Preparations for the treatment of asthmaSECTION 8 - CANCELLEDApr 1, 2008

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 21, 2022CAEXCANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9—
Jul 19, 2020REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 5, 2017NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Sep 5, 20178.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Aug 23, 2017APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 14, 2017ES8RTEAS SECTION 8 RECEIVED—
Jul 19, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 16, 2011SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jun 15, 2011REGVLAW OFFICE REGISTRATION REVIEW COMPLETED—
Jun 10, 2011CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jun 10, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 9, 2011SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jun 9, 2011EX4GSOU EXTENSION 4 GRANTED—
Jun 7, 2011IUAFUSE AMENDMENT FILED—
Jun 7, 2011EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jun 7, 2011TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Jun 7, 2011PETGPETITION TO REVIVE-GRANTED—
Jun 7, 2011PROATEAS PETITION TO REVIVE RECEIVED—
May 23, 2011MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 23, 2011ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 21, 2011EXT4SOU EXTENSION 4 FILED—
Oct 28, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 27, 2010EX3GSOU EXTENSION 3 GRANTED—
Oct 26, 2010TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Oct 26, 2010PETGPETITION TO REVIVE-GRANTED—
Oct 26, 2010PROATEAS PETITION TO REVIVE RECEIVED—
Oct 21, 2010EXT3SOU EXTENSION 3 FILED—
May 21, 2010EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 20, 2010EX2GSOU EXTENSION 2 GRANTED—
May 19, 2010TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
May 19, 2010PETGPETITION TO REVIVE-GRANTED—
May 19, 2010PROATEAS PETITION TO REVIVE RECEIVED—
Apr 21, 2010EXT2SOU EXTENSION 2 FILED—
Mar 1, 2010EX1GSOU EXTENSION 1 GRANTED—
Feb 24, 2010PGEXPETITION GRANTED - EXTENSION REQUEST FILED—
Feb 2, 2010PINMINCOMPLETE PETITION NOTICE MAILED—
Feb 2, 2010APETASSIGNED TO PETITION STAFF—
Feb 1, 2010AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 1, 2009PETRPETITION TO REVIVE-RECEIVED—
Dec 1, 2009TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Dec 1, 2009PETGPETITION TO REVIVE-GRANTED—
Dec 1, 2009PROATEAS PETITION TO REVIVE RECEIVED—
Nov 23, 2009MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 23, 2009ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 21, 2009EXT1SOU EXTENSION 1 FILED—
Apr 21, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 27, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 7, 2009NPUBNOTICE OF PUBLICATION—
Dec 22, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 16, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 15, 2008TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 15, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 15, 2008ALIEASSIGNED TO LIE—
Dec 1, 2008TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 2, 2008GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2008GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2008DOCKASSIGNED TO EXAMINER—
Feb 27, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
Feb 26, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance